摘要 : Olmutinib (Olita (TM)) is an orally bioavailable third generation epidermal growth factor receptor tyrosine kinase inhibitor. Olmutinib was approved in South Korea in May 2016 for the treatment of patients suffering from locally a... 展开
作者 | Attwa~ Mohamed W. Kadi~ Adnan A. Abdelhameed~ Ali S. |
---|---|
作者单位 | |
期刊名称 | 《Journal of separation science.》 |
总页数 | 11 |
语种/中图分类号 | 英语 / O6 |
关键词 | aldehyde intermediates iminium reactive intermediates iminoquinone intermediates olmutinib reactive metabolites |
馆藏号 | N2007EPST0002570 |